Redwood AI Expands AI Platform for Drug Development and Public Safety
Redwood AI is expanding its AI platform, Reactosphere, into new sectors including drug development and public safety. The company has announced several upgrades and collaborations with research institutions and government bodies.
Redwood AI, formerly Marshall Technologies Corp., has announced significant advancements and broader applications for its artificial intelligence platform, Reactosphere. The company has recently unveiled platform upgrades designed to accelerate drug discovery studies and expand computational processing capabilities.
The platform, rebranded as Reactosphere, has received enhancements including improved security features and expanded core functionalities. Redwood AI is also developing a new chemical risk assessment module and has updated its optimization module to enhance experimental planning and chemical process optimization.
Redwood AI is actively pursuing applications across various industries, with a notable focus on drug development and public safety. The company is collaborating with the University of British Columbia (UBC) on a research project aimed at Alzheimer's drug discovery and has partnered with Resilience Biosciences Inc. to advance small molecule drug development.
In the realm of public safety, Redwood AI is exploring AI's potential. This includes a collaboration with Aidos Innovations for public safety initiatives and an investigation into pathogen tracking using AI and genomics at the Rwanda-Democratic Republic of Congo border to potentially trace the Ebola virus. The company has also secured funding from the Government of Canada and the National Research Council of Canada for projects such as the Q-Safe chemical screening project for defense and security applications.